Literature DB >> 18337445

Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.

Malgorzata M Ptaszynska1, Michael L Pendrak, Russell W Bandle, Mary L Stracke, David D Roberts.   

Abstract

Tumor cell migration, invasion, and angiogenesis are important determinants of tumor aggressiveness, and these traits have been associated with the motility stimulating protein autotaxin (ATX). This protein is a member of the ectonucleotide pyrophosphatase and phosphodiesterase family of enzymes, but unlike other members of this group, ATX possesses lysophospholipase D activity. This enzymatic activity hydrolyzes lysophosphatidylcholine to generate the potent tumor growth factor and motogen lysophosphatidic acid (LPA). In the current study, we show a link between ATX expression, LPA, and vascular endothelial growth factor (VEGF) signaling in ovarian cancer cell lines. Exogenous addition of VEGF-A to cultured cells induces ATX expression and secretion, resulting in increased extracellular LPA production. This elevated LPA, acting through LPA(4), modulates VEGF responsiveness by inducing VEGF receptor (VEGFR)-2 expression. Down-regulation of ATX secretion in SKOV3 cells using antisense morpholino oligomers significantly attenuates cell motility responses to VEGF, ATX, LPA, and lysophosphatidylcholine. These effects are accompanied by decreased LPA(4) and VEGFR2 expression as well as by increased release of soluble VEGFR1. Because LPA was previously shown to increase VEGF expression in ovarian cancer, our data suggest a positive feedback loop involving VEGF, ATX, and its product LPA that could affect tumor progression in ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337445      PMCID: PMC2442564          DOI: 10.1158/1541-7786.MCR-07-0143

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.

Authors:  S W Nam; T Clair; C K Campo; H Y Lee; L A Liotta; M L Stracke
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

2.  Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase.

Authors:  S Rousseau; F Houle; H Kotanides; L Witte; J Waltenberger; J Landry; J Huot
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

3.  Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor.

Authors:  S W Nam; T Clair; Y S Kim; A McMarlin; E Schiffmann; L A Liotta; M L Stracke
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors.

Authors:  Suya Yang; Karen Toy; Gladys Ingle; Constance Zlot; P Mickey Williams; Germaine Fuh; Bing Li; Abraham de Vos; Mary E Gerritsen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

5.  Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.

Authors:  Yoko Hasumi; Hiroaki Mizukami; Masashi Urabe; Takahiro Kohno; Koichi Takeuchi; Akihiro Kume; Mikio Momoeda; Hiroyuki Yoshikawa; Takashi Tsuruo; Masabumi Shibuya; Yuji Taketani; Keiya Ozawa
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 6.  Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

Authors:  Gordon B Mills; Astrid Eder; Xianjun Fang; Yutaka Hasegawa; Muling Mao; Yiling Lu; Janos Tanyi; Fazal Haq Tabassam; Jon Wiener; Ruth Lapushin; Shiangxing Yu; Jeff A Parrott; Tim Compton; Walter Tribley; David Fishman; M Sharon Stack; Douglas Gaudette; Robert Jaffe; Tatsuro Furui; Junken Aoki; James R Erickson
Journal:  Cancer Treat Res       Date:  2002

7.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Authors:  Y Xu; Z Shen; D W Wiper; M Wu; R E Morton; P Elson; A W Kennedy; J Belinson; M Markman; G Casey
Journal:  JAMA       Date:  1998-08-26       Impact factor: 56.272

8.  Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase.

Authors:  Akira Tokumura; Eiji Majima; Yuko Kariya; Kyoko Tominaga; Kentaro Kogure; Katsuhiko Yasuda; Kenji Fukuzawa
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

9.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.

Authors:  Makiko Umezu-Goto; Yasuhiro Kishi; Akitsu Taira; Kotaro Hama; Naoshi Dohmae; Koji Takio; Takao Yamori; Gordon B Mills; Keizo Inoue; Junken Aoki; Hiroyuki Arai
Journal:  J Cell Biol       Date:  2002-07-15       Impact factor: 10.539

10.  Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.

Authors:  S Yamamoto; I Konishi; M Mandai; H Kuroda; T Komatsu; K Nanbu; H Sakahara; T Mori
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  33 in total

Review 1.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

2.  L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Authors:  Feng Gao; Sergio X Vasquez; Feng Su; Svetlana Roberts; Neha Shah; Victor Grijalva; Satoshi Imaizumi; Arnab Chattopadhyay; Ekambaram Ganapathy; David Meriwether; Brad Johnston; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Integr Biol (Camb)       Date:  2011-02-01       Impact factor: 2.192

3.  Association of lipid metabolism with ovarian cancer.

Authors:  M Tania; M A Khan; Y Song
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

4.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

Review 5.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 6.  Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Mari Gotoh; Yuko Fujiwara; Junming Yue; Jianxiong Liu; SueChin Lee; James Fells; Ayako Uchiyama; Kimiko Murakami-Murofushi; Stephen Kennel; Jonathan Wall; Renukadevi Patil; Renuka Gupte; Louisa Balazs; Duane D Miller; Gabor J Tigyi
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

7.  Serum autotaxin is not a useful biomarker for ovarian cancer.

Authors:  Kazuhiro Nakamura; Koji Igarashi; Ryunosuke Ohkawa; Hiromitsu Yokota; Akiko Masuda; Shunsuke Nakagawa; Tetsu Yano; Hitoshi Ikeda; Junken Aoki; Yutaka Yatomi
Journal:  Lipids       Date:  2012-06-15       Impact factor: 1.880

8.  Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.

Authors:  Aihua Xu; Md Ahsanul Kabir Khan; Fangzhi Chen; Zhaohui Zhong; Han-Chun Chen; Yuanda Song
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

Review 9.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.

Authors:  N Panupinthu; H Y Lee; G B Mills
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

Review 10.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.